The Women’s Tennis Association (WTA) introduces a new eligibility policy requiring players to complete a one-time gene test in order to compete on the women’s tour. Multiple outlets report that the WTA announces the change as applying to all players, with the policy set to take effect on Tuesday following an update issued on Sunday.
The WTA says the requirement is intended to “preserve the integrity of women’s professional tennis,” according to one report. Other coverage adds that the gene-testing requirement is linked to broader eligibility rules affecting participation, including the 2028 Los Angeles Olympics. One outlet notes that the WTA previously allowed transgender women to participate if they maintained a reduced testosterone level.
While the reports focus on the same core announcement—mandatory, one-off gene testing for women’s tour eligibility beginning this week—details about implementation, standards, and how results affect eligibility are not fully described across the cited articles. The policy’s rationale and timing are the consistent elements reported by all sources.
